Tianjin Medical University Cancer Institute And Hospital

This study tests a new combination of drugs (tunlametinib, chemotherapy, and cetuximab β) as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combo shrinks tumors and is safe. About 28 adults who have not ha…

This study tests a combination of two drugs, Sac-TMT and Tagitanlimab, in people with a type of advanced breast cancer called triple negative breast cancer that has a specific marker (PD-L1 positive). The goal is to see if the combination shrinks tumors or slows the cancer's grow…

This study is for people with esophageal cancer that did not shrink after standard pre-surgery treatment. It tests whether adding low-dose radiation to a drug called toripalimab (an immunotherapy) plus chemotherapy can help more tumors shrink before surgery. About 48 adults will …

This study tests a combination of two drugs, entinostat and oral paclitaxel, in people with a certain type of advanced breast cancer (HR+HER2-). The goal is to see if this treatment can slow down the cancer's growth. About 50 adults who have already tried 2 to 4 other treatments …

This study tests a combination of two drugs, Sacituzumab Tirumotecan and Toripalimab, as a first treatment for people with a type of advanced breast cancer called PD-L1 positive triple-negative breast cancer. The goal is to see if the combo shrinks tumors and controls the disease…

This study is for people with HER2-negative breast cancer whose tumors did not shrink after initial chemotherapy. Researchers are testing whether adding an immunotherapy drug (toripalimab) and targeted radiation before and after surgery can improve outcomes. About 110 participant…

This study tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) as the first treatment for people with a rare and aggressive type of lung cancer called large-cell neuroendocrine carcinoma, as well as similar cancers outside the lung. The goal is to see …

This study tests a combination of two drugs (utidelone and bevacizumab), with or without a third (etoposide), in 56 people with brain metastases from lung or breast cancer. The goal is to see if this treatment can shrink brain tumors and control the disease. Participants must hav…

This study tests a new approach for people with early-stage triple-negative breast cancer. Participants receive a combination of two immune-boosting drugs (iparomlimab and tuvonralimab) plus chemotherapy. After the first part of treatment, doctors check if the tumor has disappear…

This study tests a new treatment for mantle cell lymphoma, a rare blood cancer. It combines chemotherapy with targeted drugs to see if it can keep the cancer from coming back. The study involves 45 people who have not been treated before, and uses scans and blood tests to guide t…

This study tests a new drug called rilapentib alpha combined with chemotherapy before surgery for people with stage II or III non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach can shrink tumors more effectively and improve l…

This study tests whether adding the immunotherapy drug camrelizumab to chemotherapy and radiation before surgery can eliminate all signs of early-stage triple-negative breast cancer. About 43 women with newly diagnosed, untreated disease will receive the combination for 12 weeks,…

This study tests a new combination of drugs for people with advanced bile duct cancer that cannot be removed by surgery. The treatment includes chemotherapy delivered directly to the liver, an oral targeted drug, and an immunotherapy. The goal is to see if this approach can shrin…

This study tests whether a new combination of drugs (iparomlimab and tuvonralimab) plus chemotherapy can shrink tumors before surgery in people with a certain type of esophageal cancer. The goal is to see if this approach helps remove all cancer cells and improves long-term outco…

This study tests a drug called SHR-A1811 in 60 people with HER2-positive advanced breast cancer. Researchers want to see if giving the drug in different ways (like injection or infusion) can shrink tumors. The goal is to control the disease, not cure it, and participants will be …

This early-phase study tests a new cell therapy called CHT101 in 30 adults whose malignant brain tumors have come back or worsened after standard treatment. The therapy uses specially engineered cells to target a protein called CD70 found on tumor cells. The main goal is to check…

This study tests a new treatment for people with extensive-stage small cell lung cancer who have not had treatment before. The approach combines the drug bemotuzumab with standard chemotherapy and another drug called anlotinib, followed by chest radiation. The goal is to see if t…

This study tests whether giving three drugs (adebrelimab, nimotuzumab, and chemotherapy) before surgery can help people with a type of esophageal cancer. About 22 adults with resectable tumors will receive two cycles of the combination, then have surgery. The main goal is to see …

This study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can lower the chance of liver cancer coming back in people with early-stage (stage IA) liver cancer who are expected to have a narrow surgical margin. About 60 participants will be randomly ass…

This study tests a combination of two drugs, Sac-TMT and bevacizumab, in 31 adults with advanced non-squamous lung cancer that has worsened after initial chemotherapy and immunotherapy. The goal is to see if the combination can shrink tumors or slow disease progression. Participa…

This study tests a combination of two drugs, liposomal irinotecan and enlonstobart, in 30 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the combo can shrink tumors and delay cancer growth. Participants receive treatment every tw…

This study tests a drug called adebrelimab combined with chemotherapy before deciding on surgery for people with a certain type of esophageal cancer. About 200 participants will receive the treatment first. If the cancer disappears completely on scans, they will be randomly assig…

This study will follow 500 adults with HER2-positive advanced breast cancer who are starting treatment with pyrotinib. Researchers want to see how well the drug works and how safe it is in everyday medical practice, not just in a controlled trial. The main goal is to measure how …

This study tests a new combination of three drugs—becotatug vedotin, tislelizumab, and chemotherapy—for people with advanced esophageal squamous cell carcinoma (ESCC) who have not had prior treatment. The goal is to see if adding the targeted drug becotatug vedotin to standard im…

This study tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with precise radiation (SBRT) can help control early-stage non-small cell lung cancer. About 28 adults with stage I-IIB disease will receive the treatment. The goal is to see if this approac…

This study tests a daily pill called iruplinalkib in people with a specific type of early-stage lung cancer (ALK-positive, stage IA) who have high-risk features. After surgery to remove the tumor, participants take the pill for up to 3 years to see if it helps keep the cancer fro…

This study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 30 adults with early-stage liver cancer (stage IB or IIA) will receive…

This study tests a combination of three drugs (gecacitinib, donafenib, and a PD-1 inhibitor) as a second treatment for people with advanced liver cancer that did not respond to or stopped responding to initial immunotherapy. The goal is to see if this new approach can shrink tumo…

This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib or axitinib) in 36 adults with advanced clear cell kidney cancer that has worsened after initial treatment. The main goal is to see if the combination can …

This study tests whether a higher dose of furmonertinib alone works better than a standard dose combined with chemotherapy for people with a specific type of lung cancer (EGFR-mutated) that has spread to the brain. About 60 adults who have not had prior treatment will be enrolled…

This study tests a combination of two drugs (sacituzumab tirumotecan and toripalimab) given before surgery to people with stage II-IIIB non-small cell lung cancer that lacks certain genetic mutations. The goal is to see if this treatment can shrink or eliminate the cancer before …

This phase 3 study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 198 adults with early-stage liver cancer will be enrolled. The main goal is to see if this app…

This study tests whether adding a new drug (QL1706) to standard chemotherapy and targeted therapy works better than the usual approach for people with early or locally advanced HER2-positive breast cancer. About 188 participants will receive treatment before surgery to see if the…

This study tests a combination of targeted drugs (trastuzumab and pertuzumab) plus a low-dose chemotherapy (vinorelbine) given before surgery to shrink tumors in elderly patients (age 70+) with early-stage HER2-positive breast cancer. The goal is to see if this approach can elimi…

This study tests whether adding surufatinib to standard chemotherapy before surgery helps more people with high-risk or borderline resectable pancreatic cancer have a complete tumor removal. About 106 adults aged 18-75 with no prior treatment will be randomly assigned to receive …

This study tests whether giving two drugs (anlotinib and benmelstobart) before surgery can help preserve kidney function and improve outcomes for people with localized kidney cancer. About 144 participants will either receive the drugs before a partial nephrectomy or have surgery…

This study tests a combination of three drugs (donafenib, chemotherapy via infusion, and sintilimab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combo can help control the cancer longer. About 90 adults …

This study tests a combination of chemotherapy drugs (liposomal irinotecan, vincristine, and temozolomide) with or without an additional drug (anlotinib) in children aged 3-18 whose solid tumors have returned or not responded to treatment. The goal is to see if this combination c…

This study tests whether adding the experimental drug Retlirafusp alfa to standard chemotherapy helps treat gastroesophageal junction cancer. About 30 people will receive the drug combination before surgery, then some may continue the drug afterward. The goal is to see if the can…

This study tests a treatment for people whose colorectal cancer spread to the liver and was removed by surgery. After surgery, patients get chemotherapy directly into the liver artery plus standard chemo pills and IV drugs. The goal is to see if this combination helps keep cancer…

This phase 3 trial tests whether the immunotherapy drug toripalimab can help keep advanced esophageal cancer from growing after initial treatment. About 340 adults with unresectable esophageal squamous cell carcinoma who responded to chemo-immunotherapy and chemoradiation will ei…

This study tests different drug combinations for people with extensive-stage small cell lung cancer who have not had prior treatment. Participants are assigned to a treatment group based on specific markers in their tumor. The goal is to see if adding targeted therapies to standa…

This study tests a drug called fluzoparib as a long-term maintenance treatment for people with advanced triple-negative breast cancer that has responded to platinum chemotherapy. The trial includes both patients with and without BRCA gene mutations. The goal is to see if fluzopar…

This study tests a new drug combination (SHR-A1811 plus pertuzumab) given before surgery to women with early or locally advanced HR-positive, HER2-positive breast cancer. The goal is to see if this treatment can eliminate all cancer cells in the breast and lymph nodes by the time…

This study tests whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy and a targeted therapy can shrink bile duct and gallbladder cancers enough to allow surgical removal. About 29 adults with locally advanced but potentially removable…

This phase 2 trial tests whether adding an allergy medicine (diphenhydramine) to standard immunotherapy (toripalimab) and chemotherapy helps shrink lung tumors before surgery and prevents cancer from coming back after surgery. About 120 adults with stage IIA-IIIB non-small cell l…

This study tests two drug combinations to prevent nausea and vomiting in 120 breast cancer patients receiving T-DXd therapy. One group gets NEPA plus megestrol acetate, the other gets NEPA plus dexamethasone. The goal is to find which combo works better and helps patients stay on…

This study tests a new pain medicine called anrikefon in 114 adults having keyhole surgery to remove part of the stomach for cancer. The drug targets pain outside the brain, so it may cause fewer side effects like drowsiness or addiction. The goal is to see if it reduces the need…

This study tests a drug called romiplostim N01 in 68 breast cancer patients whose platelet counts dropped too low due to chemotherapy. The goal is to see if a weekly injection can safely bring platelet levels back to normal within two weeks, helping patients continue their cancer…

This study looks at 860 Chinese patients with advanced kidney cancer to see which order of treatments works better: starting with one drug combo and switching to another, or the reverse. The goal is to find the best sequence to help patients live longer and feel better. Participa…

This study looks at 300 lung cancer patients whose tumors did not fully disappear after immunotherapy before surgery. Researchers will use advanced DNA and RNA testing to find hidden gene changes that might explain why the treatment didn't work completely. The goal is to better u…